Fruquintinib Provides Meaningful Benefit in Refractory Metastatic CRC
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
THURSDAY, July 20, 2023 -- For patients with refractory metastatic colorectal cancer, fruquintinib treatment yields a significant and clinically meaningful benefit in terms of overall survival, according to a study published in the July 1 issue of The Lancet.
Arvind Dasari, M.D., from the University of Texas MD Anderson Cancer Center in Houston, and colleagues conducted an international, randomized, double-blind phase 3 study at 124 hospitals and cancer centers across 14 countries. Patients aged 18 years or older with histologically or cytologically documented metastatic colorectal adenocarcinoma who had received all current standard approved cytotoxic and targeted therapies and progressed on or were intolerant to trifluridine-tipiracil or regorafenib, or both, were included. A total of 691 patients were randomly assigned (2:1) to receive fruquintinib (5 mg capsule) or matched placebo orally once daily on days 1 to 21 followed by an off-week in 28-day cycles, plus best supportive care (461 and 230 patients, respectively).
The researchers found that median overall survival was 7.4 and 4.8 months in the fruquintinib and placebo groups, respectively (hazard ratio, 0.66). Grade 3 or worse adverse events occurred in 63 and 50 percent of patients receiving fruquintinib and placebo, respectively; the most common grade 3 or worse adverse events included hypertension, asthenia, and hand-foot syndrome in the fruquintinib group (14, 8, and 6 percent, respectively).
"The significant and clinically meaningful benefit with fruquintinib, the true extent of which will be more clear following analyses of the quality of life assessments, was coupled with a favorable safety profile," the authors write.
Several authors disclosed ties to biopharmaceutical companies, including HUTCHMED, which manufactures fruquintinib and funded the study.
Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted July 2023
Read this next
Diagnosis of Early-Onset Colorectal Cancer Often Delayed
WEDNESDAY, May 29, 2024 -- Nearly half of individuals diagnosed with early-onset colorectal cancer (EOCRC) present with hematochezia and abdominal pain, and one-quarter present...
Offering Choice of CRC Screening Increases Completion Rates
TUESDAY, May 21, 2024 -- For adults who are not up to date with colorectal cancer screening, offering a choice of colonoscopy or fecal immunochemical testing (FIT) increases...
DDW: 1999 to 2020 Saw Rise in Incidence of Colorectal Cancer in People Under 45
MONDAY, May 13, 2024 -- For individuals aged younger than 45 years, the incidence of colorectal cancer increased considerably from 1999 to 2020, with a 333 percent increase among...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.